In recent years, structured RNAs have become tractable drug targets, enabling the discovery of selective modulators for riboswitches, long noncoding RNAs, G-quadruplexes, and RNA–protein complexes.
Breakthrough advances in library design, screening methodologies, and AI-based prioritization have expanded the scope of RNA-targeted drug discovery (Kovachka et al., Nat Rev Chem 2024; Lundquist et al., SLAS Discovery 2025; Morishita, ChemMedChem 2022; Momentum Bio, 2024).
Modern RNA-focused screening now combines:

• Affinity Selection–Mass Spectrometry (AS-MS) for label-free, solution-phase discovery,

• SPR/BLI for kinetic profiling and specificity ranking,

• AI-guided virtual enrichment to prioritize compounds with high “RNA-likeness” before experimental testing (Graff et al., Chem Sci 2020; Cao et al., Nat Mach Intell 2023).